SOURCE: Fresenius Medical Care

Fresenius Medical Care

April 06, 2017 04:59 ET

Fresenius Medical Care completes acquisition of a 70% equity interest in Kunming Wuhua Healthcare Hospital Co. Ltd.

SHANGHAI, CHINA--(Marketwired - Apr 6, 2017) - Fresenius Medical Care, the world's leading provider of dialysis products and services announces the acquisition of 70% equity interest in Kunming Wuhua Health Hospital (Wuhua Hospital) in China, specialized in chronic-disease management and hemodialysis (HD). The acquisition was officially completed on March 31th, 2017. This marks Fresenius Medical Care's first joint venture (JV) hospital in China, with the aim of providing high-standard renal-care services and chronic-disease management to local communities.

There are 900,000 people living in Wuhua district and 9.8 million residents in Kunming City. Wuhua Hospital is a private Grade II hospital located in Wuhua district in the center of Kunming city, the capital of Yunnan province in south-west China. With more than 30 years history, the facility now offers treatments to more than 8,000 chronic-disease patients and 70 dialysis patients. The scope of services includes internal medicine, nephrology, surgery, gynecology, dermatology, traditional Chinese medicine, physiotherapy, stomatology and etc.

Chronic-disease management will be gradually migrated from larger hospital outpatient departments to smaller Grade II hospitals and community hospitals, according to a new policy issued by the China State Council and the National Health and Family Planning Commission.

As the first JV hospital in mainland China, the new Wuhua Hospital will continue chronic-disease management whilst improving services, competency enhancement, quality control, and expand the current HD business, including developing peritoneal dialysis and vascular-surgery business opportunities.

As a milestone partnership and best practice case for China, Fresenius Medical Care will continue to seek collaboration with the public and private sector partners to extend its expertise and services to provide integrated high-standard holistic care to local renal patients while increasing the benefits to more patients.

Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,624 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 308,471 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FRANKFURT: FME) and on the New York Stock Exchange (NYSE: FMS).
For more information visit the company's website at

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Contact Information

  • Eonjung Lim
    Director Marketing Communications
    Fresenius Medical Care
    T +852 2583 0888
    F +852 2583 0262